The effect of brexpiprazole in adult outpatients with early-episode schizophrenia: an exploratory study

The aim of this study was to evaluate flexibly dosed brexpiprazole for early-episode schizophrenia through the assessment of efficacy, social functioning, and tolerability. This was an exploratory, 16-week, open-label, flexible-dose (1, 2, 3, or 4 mg/day; target dose 3 mg/day) study in outpatients with early-episode schizophrenia (18–35 years old, ≤5 years’ duration of illness).

להמשך קריאה